Eleftha 375 mg Injection 1's

Eleftha 375 mg Injection 1's is an anti-cancer medicine used in the treatment of HER2-positive Breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. Cancer is a disease where the cells grow abnormally and divide uncontrollably. It can also be used when the cancer has spread to other parts of the body.

Eleftha 375 mg Injection 1's contains Trastuzumab as an active ingredient, which belongs to the class of monoclonal antibodies. It works by inhibiting the abnormal growth of cancer cells and, finally, causes the initiation of programmed cell death.

Eleftha 375 mg Injection 1's may cause certain side effects such as abdominal pain, chills, diarrhoea, fatigue, nausea, back pain, bone pain, edema, insomnia, fever, dizziness, headache, vomiting, cough, rash, and injection site reactions. If the side effects persist or bother you, please consult your doctor. Eleftha 375 mg Injection 1's will be administered by a trained doctor. Hence, do not self-administer.

Avoid taking it and inform your doctor if you are allergic to Eleftha 375 mg Injection 1's or its components. Inform your doctor if you have any cardiovascular conditions, lung problems, or liver/kidney disease, as it can cause adverse effects. Eleftha 375 mg Injection 1's is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand.

Eleftha 375 mg Injection 1's contains Trastuzumab, which is used for treating patients with HER2-positive breast cancer and HER2-positive metastatic gastroesophageal adenocarcinoma. This medicine works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of programmed cell death.

• Nausea
• Vomiting
• Diarrhoea
• Myalgia
• Bone pain
• Headache
• Fatigue
• Injection site reactions
• Pain at the site of injection
• Dizziness
• Edema
• Cough
• Rash
• Insomnia

Eleftha 375 mg Injection 1's should be avoided if you are allergic to it or any other components of this medicine. Inform your doctor if you have any lung problems, cardiovascular conditions or liver/kidney disease, as it can cause adverse effects. Eleftha 375 mg Injection 1's may cause left ventricular ejection fraction, cardiomyopathy, pulmonary toxicity, exacerbations of chemotherapy-induced neutropenia, and hypersensitivity reactions during the treatment. Hence, careful observation should be performed for any reactions in the patient. Eleftha 375 mg Injection 1's may cause embryo-fetal toxicity. Hence, if you are pregnant or planning to become pregnant, inform your doctor beforehand. Breastfeeding should be discontinued in nursing mothers during the treatment. Eleftha 375 mg Injection 1's is not recommended for use in children as the safety and efficacy are not established.

Drug-Drug Interactions: Eleftha 375 mg Injection 1's may interact with monoclonal antibodies (etanercept, golimumab, infliximab, natalizumab), antiviral drugs (indinavir, efavirenz, atazanavir), live vaccines, etc.

Drug-Food Interactions: No interaction found.

Drug-Disease Interactions: Inform your doctor if you have cardiac problems, lung disease, liver/kidney disease or allergic reactions.

• ETANERCEPT
• NATALIZUMAB
• INDINAVIR
• EFAVIRENZ
• ATAZANAVIR
• GOLIMUMAB

• Meditation and yoga have been proven very effective in helping cancer patients maintain a healthy attitude and body.
• Eat more lean meats, healthy fats, fruits, vegetables, and whole-grain foods to give you more energy. 
• Stay hydrated by drinking plenty of water, as dehydration is often seen in cancers.
• Taking a stroll in the garden or spending 30 minutes of your time doing some light physical activity can be very useful. However, do not over-exert yourself if you feel too tired. 
• Avoid smoking and alcohol consumption.

• Avoid intercourse while on treatment with Eleftha 375 mg Injection 1's.
• Regular, complete blood count monitoring is advised during the treatment.
• All patients should be tested for HER2 test before starting the treatment regimen.
• Liver function tests (LFT) and pulmonary function tests (PFT) should be performed before starting the treatment and every 4 to 6 weeks during the treatment.
• Regular ECG and electrolytes should be monitored while taking the medicine.

Breast Cancer: Breast cancer is a type of cancer with abnormal growth in the cells of the breast. There are different kinds of breast cancer, such as cancer occurring in lobules (glands that produce milk), ducts of the breast (the pathway that brings milk from glands to the nipple), and in the fatty tissue or the fibrous connective tissue within the breast. Symptoms of breast cancer include a lump in the breast, breast pain, redness, swelling, nipple discharge other than breast milk, bloody discharge, a lump or swelling under the arm, unexplained change in shape, size or appearance of the breast, peeling, flaking or scaling of the skin. 

Stomach Cancer (Gastric adenocarcinoma): It is a type of cancer that develops from the stomach lining. When the cancer cells spread to other organs of the body, it is called metastatic. This condition can occur mainly due to smoking, a highly processed or salty diet, and severe bacterial infection of H. pylori. Symptoms of stomach cancer include feeling bloated after eating, feeling full after eating small amounts of food, nausea, heartburn or indigestion.